Rallybio Corp.(RLYB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

RLYB Rallybio Corp.

Closed Good Friday 04-02 16:00:00 EDT

8.43

+0.03

+0.36%

盘后8.43

+0.000.00%

16:10 EDT

High8.45	Low8.20	Vol14.57K
Open8.24	D1 Closing8.40	Amplitude2.98%
Mkt Cap44.51M	Tradable Cap21.41M	Total Shares5.28M
T/O121.67K	T/O Rate0.57%	Tradable Shares2.54M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"RLYB","market":"US","secType":"STK","nameCN":"Rallybio Corp.","latestPrice":8.43,"timestamp":1775160000000,"preClose":8.4,"halted":0,"volume":14565,"hourTrading":{"tag":"盘后","latestPrice":8.43,"preClose":8.43,"latestTime":"16:10 EDT","volume":1,"amount":8.43,"timestamp":1775160604574,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.003571428571428495,"floatShares":2539587,"shares":5280471,"eps":-1.59,"marketStatus":"Closed Good Friday","change":0.03,"latestTime":"04-02 16:00:00 EDT","open":8.24,"high":8.45,"low":8.2,"amount":121671.1153,"amplitude":0.029762,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.59,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1775462400000},"marketStatusCode":7,"adr":0,"listingDate":1627531200000,"exchange":"NASDAQ","adjPreClose":8.4,"postHourTrading":{"tag":"盘后","latestPrice":8.43,"preClose":8.43,"latestTime":"16:10 EDT","volume":1,"amount":8.43,"timestamp":1775160604574,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.19034189667438686},"requestUrl":"/m/hq/s/RLYB/wiki","defaultTab":"wiki","newsList":[{"id":"2624355435","title":"Rallybio CMO Departs Amid Pending Candid Therapeutics Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2624355435","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624355435?lang=en_us&edition=fundamental","pubTime":"2026-04-01 07:40","pubTimestamp":1775000410,"startTime":"0","endTime":"0","summary":"Rallybio ( ($RLYB) ) has issued an announcement. On March 31, 2026, Rallybio Corporation announced that Chief Medical Officer Steven Ryder, M.D., w...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/rallybio-cmo-departs-amid-pending-candid-therapeutics-merger?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/rallybio-cmo-departs-amid-pending-candid-therapeutics-merger?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RLYB","BK4007","LENZ","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624537496","title":"Rallybio Chief Medical Officer Steven Ryder departs effective immediately","url":"https://stock-news.laohu8.com/highlight/detail?id=2624537496","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624537496?lang=en_us&edition=fundamental","pubTime":"2026-04-01 04:11","pubTimestamp":1774987886,"startTime":"0","endTime":"0","summary":"Rallybio announced Chief Medical Officer Steven Ryder will leave effective immediately.Departure follows Ryder’s tenure in role since January 2019.Equity awards remain outstanding under terms tied to pending business combination with Candid Therapeutics.Options will remain exercisable until 90 days following closing of merger.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rallybio Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 31, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDL5PYpHH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RLYB","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620828284","title":"Rallybio CVRs Carry High Risk of Expiring Worthless Amid Uncertain Asset Monetization","url":"https://stock-news.laohu8.com/highlight/detail?id=2620828284","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620828284?lang=en_us&edition=fundamental","pubTime":"2026-03-18 14:00","pubTimestamp":1773813659,"startTime":"0","endTime":"0","summary":"Rallybio Corporation (RLYB) has disclosed a new risk, in the Share Price & Shareholder Rights category. The risk factor highlights that Rallybio Co...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/rallybio-cvrs-carry-high-risk-of-expiring-worthless-amid-uncertain-asset-monetization?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/rallybio-cvrs-carry-high-risk-of-expiring-worthless-amid-uncertain-asset-monetization?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","RLYB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620492357","title":"Rallybio FY2025 net loss narrowed 84.46% to USD 8.98 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2620492357","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620492357?lang=en_us&edition=fundamental","pubTime":"2026-03-17 05:19","pubTimestamp":1773695970,"startTime":"0","endTime":"0","summary":"Rallybio published its annual report on Form 10-K for FY 2025, reporting a net loss of USD 8.98 million. Collaboration and license revenue rose 34.91% to USD 0.86 million. Research and development expenses fell 52.79% to USD 19.6 million, primarily due to lower RLYB212 costs after the program was discontinued in April 2025 and lower headcount. General and administrative expenses decreased 27% to USD 14.33 million, driven mainly by lower personnel-related expenses and reduced professional fees. Cash, cash equivalents and marketable securities totaled USD 54.7 million as of Dec. 31, 2025, and management said it expects this to fund operating expenses and capital expenditure requirements into 2028.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDLbM7jY1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RLYB","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617272631","title":"Rallybio Completes Key FNAIT Risk Study, Laying Groundwork for Future Market Moves","url":"https://stock-news.laohu8.com/highlight/detail?id=2617272631","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617272631?lang=en_us&edition=fundamental","pubTime":"2026-03-07 00:32","pubTimestamp":1772814722,"startTime":"0","endTime":"0","summary":"Rallybio Corporation ($RLYB) announced an update on their ongoing clinical study. The Rallybio (RLYB) study, officially titled “A Prospective, Natu...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/rallybio-completes-key-fnait-risk-study-laying-groundwork-for-future-market-moves?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/rallybio-completes-key-fnait-risk-study-laying-groundwork-for-future-market-moves?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","RLYB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616330335","title":"Rallybio in Reverse Merger With Candid Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2616330335","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616330335?lang=en_us&edition=fundamental","pubTime":"2026-03-02 21:36","pubTimestamp":1772458560,"startTime":"0","endTime":"0","summary":"Rallybio has inked a deal to combine with fellow clinical-stage biotechnology company Candid Therapeutics in an all-stock reverse merger.Rallybio on Monday said its shareholders will own about 3.65% of the combined company, while Candid's investors will own the rest.A reverse merger allows a private company to go public by merging with a public one at a lower cost than is involved in traditional initial public offerings.Rallybio said the combined company will operate under the name Candid Therapeutics and trade on Nasdaq under the symbol CDRX upon completion of the deal, slated for mid-2026.Rallybio said Candid, which is advancing a portfolio of T-cell engager therapeutics for autoimmune diseases, has agreements for more than $500 million in financing from a syndicate of healthcare institutional investors and mutual funds that will fund operations through 2030.The New Haven, Conn., company said its shareholders will receive contingent value rights entitling them to part of the cash pro","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LENZ","RLYB","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616033717","title":"BRIEF-Rallybio Corporation And Candid Therapeutics Announce Merger Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2616033717","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616033717?lang=en_us&edition=fundamental","pubTime":"2026-03-02 21:24","pubTimestamp":1772457843,"startTime":"0","endTime":"0","summary":"BRIEF-Rallybio Corporation And Candid Therapeutics Announce Merger AgreementMarch 2 (Reuters) - Rallybio Corp RLYB.O:RALLYBIO CORPORATION AND CANDID THERAPEUTICS ANNOUNCE MERGER AGREEMENTRALLYBIO CORP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nTUA47TQPH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RLYB","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616233226","title":"Rallybio Corp - Combined Company to Operate as Candid Therapeutics Under Ticker Cdrx","url":"https://stock-news.laohu8.com/highlight/detail?id=2616233226","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616233226?lang=en_us&edition=fundamental","pubTime":"2026-03-02 21:03","pubTimestamp":1772456615,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nFWN3ZQ0T7:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4539","RLYB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616051332","title":"Rallybio Corp - Candid Secures Oversubscribed and Upsized Private Financing of Over $505 Mln in Gross Proceeds","url":"https://stock-news.laohu8.com/highlight/detail?id=2616051332","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616051332?lang=en_us&edition=fundamental","pubTime":"2026-03-02 21:03","pubTimestamp":1772456615,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nFWN3ZQ0T7:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RLYB","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616017332","title":"Rallybio Corp - Co's Equityholders to Own 3.65% of Combined Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2616017332","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616017332?lang=en_us&edition=fundamental","pubTime":"2026-03-02 21:03","pubTimestamp":1772456615,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nFWN3ZQ0T7:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","RLYB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616449332","title":"Rallybio Corp: Pre-Transaction Rallybio Equityholders Are Expected to Own Approximately 3.65% of Combined Co","url":"https://stock-news.laohu8.com/highlight/detail?id=2616449332","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616449332?lang=en_us&edition=fundamental","pubTime":"2026-03-02 21:00","pubTimestamp":1772456403,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nTUA47TQPH:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","RLYB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616332978","title":"Rallybio Corp - Over $505 Mln Financing Committed by Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2616332978","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616332978?lang=en_us&edition=fundamental","pubTime":"2026-03-02 21:00","pubTimestamp":1772456403,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nTUA47TQPH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4539","RLYB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616324783","title":"Rallybio Corp - Ken Song to Lead Combined Company as CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2616324783","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616324783?lang=en_us&edition=fundamental","pubTime":"2026-03-02 21:00","pubTimestamp":1772456403,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nTUA47TQPH:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","RLYB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616324473","title":"Rallybio Corp - Pro-Forma Cash of About $700 Mln Expected at Closing","url":"https://stock-news.laohu8.com/highlight/detail?id=2616324473","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616324473?lang=en_us&edition=fundamental","pubTime":"2026-03-02 21:00","pubTimestamp":1772456403,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nTUA47TQPH:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","RLYB","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616324453","title":"Rallybio Corp: Combined Company's Cash Balance at Closing Is Expected to Fund Operations Through 2030","url":"https://stock-news.laohu8.com/highlight/detail?id=2616324453","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616324453?lang=en_us&edition=fundamental","pubTime":"2026-03-02 21:00","pubTimestamp":1772456403,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nTUA47TQPH:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","RLYB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616332497","title":"Press Release: Rallybio Corporation and Candid Therapeutics Announce Merger Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2616332497","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616332497?lang=en_us&edition=fundamental","pubTime":"2026-03-02 21:00","pubTimestamp":1772456400,"startTime":"0","endTime":"0","summary":"Combined company to operate as Candid Therapeutics, advancing a leading portfolio of T-cell engager therapeutics for autoimmune diseases. Concurrent significantly oversubscribed and upsized financing of over $505 million committed by a syndicate of leading healthcare institutional investors and mutual funds expected to fund operations through 2030. The Transaction has been unanimously approved by the boards of directors of both companies and is expected to close in mid-2026, subject to certain closing conditions, including the approval by the stockholders of each company, the effectiveness of a registration statement to be filed with the Securities and Exchange Commission  to register the shares of Rallybio common stock to be issued in connection with the Transaction, the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and the satisfaction of other customary closing conditions. Following closing, pre-Transaction Rallybio equityholders are expecte","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4539","RLYB","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616332538","title":"NASDAQ TRADE HALT  HALT NEWS PENDING AT 07:55 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2616332538","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616332538?lang=en_us&edition=fundamental","pubTime":"2026-03-02 20:55","pubTimestamp":1772456100,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  HALT NEWS PENDING AT 07:55 AM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nAQN2LOFAQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RLYB","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614863115","title":"Rallybio’s RLYB116 Clears Phase 1 Milestone, Sharpening Its Autoimmune Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2614863115","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614863115?lang=en_us&edition=fundamental","pubTime":"2026-02-28 00:33","pubTimestamp":1772210012,"startTime":"0","endTime":"0","summary":"Rallybio Corporation ($RLYB) announced an update on their ongoing clinical study. Rallybio (RLYB) has completed a Phase 1 trial titled “Multiple Do...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/rallybios-rlyb116-clears-phase-1-milestone-sharpening-its-autoimmune-pipeline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/rallybios-rlyb116-clears-phase-1-milestone-sharpening-its-autoimmune-pipeline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","RLYB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612659234","title":"Rallybio Shares Successful Early-Stage Results for Rare Disease Drug; New Trial Set for Late 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2612659234","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612659234?lang=en_us&edition=fundamental","pubTime":"2026-02-17 23:46","pubTimestamp":1771343160,"startTime":"0","endTime":"0","summary":"Rallybio reports strong Phase 1 results for RLYB116, showing full immune pathway control with good safety and Phase 2 plans ahead.","market":"nz","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/02/17/biotech-lab.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/02/17/biotech-lab.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/26/02/50655870/rallybio-shares-successful-early-stage-results-for-rare-disease-drug-new-trial-set-for-late-2026","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/26/02/50655870/rallybio-shares-successful-early-stage-results-for-rare-disease-drug-new-trial-set-for-late-2026","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["SSI","BK4217","SMA","BK4539","BK4139","RLYB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612574514","title":"BRIEF-Rallybio Announces Positive Data For RLYB116 Phase 1 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2612574514","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612574514?lang=en_us&edition=fundamental","pubTime":"2026-02-17 21:37","pubTimestamp":1771335456,"startTime":"0","endTime":"0","summary":"BRIEF-Rallybio Announces Positive Data For RLYB116 Phase 1 StudyFeb 17 (Reuters) - Rallybio Corp RLYB.O:RALLYBIO ANNOUNCES POSITIVE DATA FOR RLYB116 PHASE 1 STUDY DEMONSTRATING COMPLETE AND SUSTAINED ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nTUA9LF1DQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","RLYB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.rallybio.com","stockEarnings":[{"period":"1week","weight":-0.0012},{"period":"1month","weight":-0.2125},{"period":"3month","weight":0.4898},{"period":"6month","weight":0.8654},{"period":"1year","weight":0.8168},{"period":"ytd","weight":0.5359}],"compareEarnings":[{"period":"1week","weight":0.0166},{"period":"1month","weight":-0.036},{"period":"3month","weight":-0.04},{"period":"6month","weight":-0.02},{"period":"1year","weight":0.1617},{"period":"ytd","weight":-0.0383}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.05452},{"month":2,"riseRate":0.6,"avgChangeRate":0.213566},{"month":3,"riseRate":0.2,"avgChangeRate":-0.14957},{"month":4,"riseRate":0.4,"avgChangeRate":-0.03251},{"month":5,"riseRate":0.5,"avgChangeRate":0.132316},{"month":6,"riseRate":0.25,"avgChangeRate":-0.189526},{"month":7,"riseRate":1,"avgChangeRate":0.176338},{"month":8,"riseRate":0.4,"avgChangeRate":-0.034234},{"month":9,"riseRate":0.6,"avgChangeRate":0.045433},{"month":10,"riseRate":0.6,"avgChangeRate":0.040053},{"month":11,"riseRate":0.2,"avgChangeRate":-0.230437},{"month":12,"riseRate":0.6,"avgChangeRate":0.001492}],"exchange":"NASDAQ","name":"Rallybio Corp.","nameEN":"Rallybio Corp."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Rallybio Corp.(RLYB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Rallybio Corp.(RLYB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Rallybio Corp.,RLYB,Rallybio Corp.股票,Rallybio Corp.股票老虎,Rallybio Corp.股票老虎国际,Rallybio Corp.行情,Rallybio Corp.股票行情,Rallybio Corp.股价,Rallybio Corp.股市,Rallybio Corp.股票价格,Rallybio Corp.股票交易,Rallybio Corp.股票购买,Rallybio Corp.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Rallybio Corp.(RLYB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Rallybio Corp.(RLYB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}